Bio-Rad Laboratories, Inc. (NYSE:BIO) Shares Purchased by Moran Wealth Management LLC

Moran Wealth Management LLC grew its position in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 3.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,429 shares of the medical research company’s stock after purchasing an additional 80 shares during the period. Moran Wealth Management LLC’s holdings in Bio-Rad Laboratories were worth $798,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in BIO. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Bio-Rad Laboratories by 67.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,588 shares of the medical research company’s stock worth $3,478,000 after buying an additional 4,256 shares in the last quarter. Larson Financial Group LLC boosted its position in Bio-Rad Laboratories by 11.6% during the 4th quarter. Larson Financial Group LLC now owns 1,143 shares of the medical research company’s stock worth $375,000 after acquiring an additional 119 shares during the period. Candriam S.C.A. grew its stake in shares of Bio-Rad Laboratories by 7.0% in the fourth quarter. Candriam S.C.A. now owns 33,747 shares of the medical research company’s stock worth $11,086,000 after purchasing an additional 2,220 shares in the last quarter. Raymond James Financial Inc. acquired a new position in shares of Bio-Rad Laboratories during the fourth quarter valued at $5,119,000. Finally, Proficio Capital Partners LLC bought a new stake in shares of Bio-Rad Laboratories during the fourth quarter valued at about $9,820,000. Institutional investors and hedge funds own 65.24% of the company’s stock.

Analyst Upgrades and Downgrades

BIO has been the subject of a number of recent analyst reports. Wells Fargo & Company decreased their target price on shares of Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 12th. StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $481.00 price objective on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Price Performance

Shares of Bio-Rad Laboratories stock opened at $251.17 on Wednesday. Bio-Rad Laboratories, Inc. has a 52 week low of $244.19 and a 52 week high of $387.99. The company has a current ratio of 6.48, a quick ratio of 4.85 and a debt-to-equity ratio of 0.18. The stock has a market cap of $7.04 billion, a PE ratio of -3.86 and a beta of 0.99. The company’s 50-day moving average price is $316.63 and its two-hundred day moving average price is $329.48.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. As a group, sell-side analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.